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Poster Session I 95minimally invasive assays to be used following mass radiation expo-
sure from biological information stored in the human body. Study
Aim: The goals of this study were to: 1.) identify potential bio-
dosimetry genes from cancer patients following total body irradia-
tion (TBI); 2.) use gene expression analysis in an in vitro system to
develop mathematical models capable of determining radiation
dose received by exposed individuals. Methods/Results: Blood
samples were collected at 5 and 23 hours post-TBI from three pa-
tients with acute lymphocytic leukemia treated over three days
with 2 daily 2 Gy fractions (12 Gy total). Low density array analysis
revealed 15 genes with increased expression post-irradiation. In vi-
tro studies utilized immortalized B lymphocytes irradiated at 0.1,
0.5, 1, and 2 Gy and harvested 3, 5, 9, 12, and 23 hours post-irradi-
ation. Of the 15 genes identified in patients, 10 demonstrated sim-
ilar expression profiles in B lymphocytes. Leukemia Inhibitory
Factor (LIF) and Serine Protease Inhibitor E1 (SERPINE1) dis-
played linear dose-dependent increases in expression at every
time-point as determined by linear regression analyses (r2-val-
ues$0.76, p\ 0.0001). LIF and SERPINE1 followed a time-de-
pendent cubic model of expression to be validated in expanded
time-point studies. Conclusion: The determination of LIF and
SERPINE1 expression may be useful in determining dose of radia-
tion exposure and may subsequently facilitate stratification of indi-
viduals requiring medical intervention.SUPPORTIVE CARE257
DECREASE OF HHV6 DNAemia FOLLOWING ALLOGENEIC HEMATOPOI-
ETIC STEM CELL TRANSPLANTATION IN PATIENTS WITH CHROMOSO-
MALLY INTEGRATED HHV6
Hubacek, P.1, Hrdlickova, A.2, Muzikova, K.1, Hyncicova, K.2,
Pohlreich, D.3, Cetkovsky, P.3, Sedlacek, P.1. 1Teaching Hospital Motol,
2ndMedical School, Charles University, Prague, Czech Republic; 2Teach-
ing Hospital Motol, 2nd Medical School, Charles University, Prague,
Czech Republic; 3 Institute of Hematology and Blood Transfusion, Prague,
Czech Republic.
Immunocompromised patients could suffer from clinical conse-
quences of infection with the human herpesvirus 6 (HHV6). Using
PCRmethods, we are now able to detect viremia while serology re-
sults might be inconclusive in this cohort of patients. Phenomenon
of chromosomal integration of HHV6 (CI-HHV6) however
opened new era in interpretation of HHV6 PCR positivity. Since
CI-HHV6 could be inherited from parent, viral DNA can be de-
tected in every body cell. CI-HHV6 does not represent active
HHV6 infection and its prevalence in population is described be-
tween 1–2%. In such situation, misinterpretation of PCR positivity
may than lead to inadequate and potentially harmful therapy due to
risks of unsubstantiated toxicity and side effects.
In situation of allogeneic HSCT, it is possible to observe increase
in HHV6 positivity caused by the engraftment of the cells from CI-
HHV6 positive donor, or decrease in detected HHV6 DNA after
HSCT in CI-HHV6 positive recipient transplanted with the donor
without CI-HHV6.
Between I/2002-X/2007 we have tested for HHV6 2057 samples
from 219 adult patients and 2553 samples from 107 children
patients after allogeneic HSCT. DNA was isolated from whole
blood and detection was performed using RQ-PCR. Results
were normalised to 10,000 human genomic equivalents accessed
by quantification of albumin gene. HHV6 was detected in 395
samples from 58 children and 144 samples from 40 adults. Within
three weeks after HSCT, we have detected more then 1,000 nor-
malised viral copies in 7 children and 4 adults. From these, we have
confirmed CI-HHV6 by documenting positivity in the pre-trans-
plant samples and the non-blood samples (hair follicles) in one
child and one adult. CI-HHV6 is highly probable also in two pa-
tients with variant B due to long lasting PCR positivity in post-
transplant surveillance and decrease shortly after HSCT (we are
working on CI-HHV6 confirmation). In none of the patients we
have observed post-transplant complications attributable to
HHV6. We excluded CI-HHV6 by the pre-transplant negativity
in the 7 remaining patients.Despite HHV6 is close related to human cytomegalovirus, in this
particular situation patients are endangered only by misinterpreta-
tion of highly positive viral DNA load and side effects of virostatics.
Therefore in case of high HHV6 DNA load we should be aware of
this phenomenon and we should try to excludeCI-HHV6 as soon as
possible.
Supported by FNM 00064203, MSMT0021620813.258
VORICONAZOLE IS EFFECTIVE PROPHYLAXIS FOR ASPERGILLUS INVA-
SIVE FUNGAL INFECTION (IFI) IN PATIENTS RECEIVING GLUCOCORTI-
COSTEROID THERAPY FOR GVHD AFTER ALLOGENEIC
TRANSPLANTATION
Gergis, U.1, Markey, K.2, Greene, J.1, Kharfan-Dabaja, M.1,
Wetzstein, G.2, Anasetti, C.1, Perkins, J.1. 1H. Lee Moffitt Cancer Cen-
ter & Research Institute, Tampa, FL; 2H. Lee Moffitt Cancer Center &
Research Institute, Tampa, FL.
Invasive fungal infections (IFI) are a significant cause of morbid-
ity and mortality after allogeneic hematopoietic cell transplant. Pa-
tients (pts) who develop graft versus host disease (GVHD) requiring
systemic glucocorticoids (GC) are especially vulnerable to IFI. The
findings of Ullmann et al. support the prophylactic use of posacona-
zole over either fluconazole (F) or itraconazole (I) in this pt popula-
tion. Efficacy of posaconazole, however, can be limited in pts with
gastrointestinal GVHDby the lack of an IV formulation. Voricona-
zole (V) offers advantages over posaconazole in the availability of an
IV formulation and improved oral bioavailability. Following FDA
approval, we began using V for prophylaxis in patients with
GVHD at the onset of GC therapy. Prior to that time either F or
I was given. To determine the antifungal efficacy of V compared
to F or I, we performed a retrospective review of 169 allogeneic
transplant pts who were placed on GC ($1 mg/kg/d of prednisone
or equivalent) for GVHD. Pts with IFI history before GVHDonset
were excluded. Study endpoints included proportion of pts with
proven or probable IFI by EORTC/MSG criteria during the first
100 days of GC therapy, time to IFI, and mortality due to IFI diag-
nosed within 100 days of the start of GC. Seventy-two pts received
either F (36 pts) or I (36 pts) (F/I) and 97 pts received V. V pts were
older, had higher risk disease, were more likely to have received
transplants of peripheral blood hematopoietic cells and from unre-
lated donors (all risk factors for GVHD and secondary IFI), but
were treated more recently and with reduced intensity regimens.
IFI developed in 7 F/I pts (9.7%) vs 2 V pts (2.1%) (p 5 0.03). F/
I pts included 5 cases (6.9%) of aspergillus (pneumonia [4] and
skin abcess [1]), and 2 cases of candidemia [C. krusei and C. glab-
rata]. V pts included 2 cases of candidemia (C. glabrata) and no as-
pergillus IFI. The proportion of pts developing aspergillus IFI was
significantly lower in the V pts (p 5 0.009). Five of the seven F/I
cases died from the IFI, one of pulmonary hemorrhage and one of
bacterial sepsis. Neither of the 2 V pts died as a result of their
IFI, one died from CNS hemorrhage and the other from GVHD.
Overall survival at 100 days after start of GC was 79% for F/I pts
and 85% for V pts (p 5 0.27). We conclude that voriconazole was
effective prophylaxis for aspergillus IFI in pts receiving GC therapy
for GVHD after allogeneic transplantation.259
TREATMENT OF DONOR GRAFT FAILURE WITH AUTOLOGOUS OR ALLO-
GENEIC STEM CELL BOOST OR A SECOND ALLOGENEIC TRANSPLANT
BASED ON CHIMERISM TESTING
Shimoni, A., Shem-Tov, N., Rand, A., Ribakovsky, E., Yerushalmi, R.,
Hardan, I., Nagler, A. Chaim Sheba Medical Center, Tel-Hashomer,
Israel.
Donor graft failure (GF) is a life-threatening complication of al-
logeneic stem cell transplantation (SCT). We performed this anal-
ysis to determine the rate and outcome of GF in the era of modern
SCT. We retrospectively reviewed data of 491 SCTs from HLA-
matched siblings (n 5 284), matched-unrelated (MUD, n 5 180)
96 Poster Session Ior alternative donors (mismatched-related, haplo-identical and
cord-blood, n 5 27) performed in a single institution since 1/
2001. GF was diagnosed in 25 patients (pts), cumulative incidence
(CI) 5.2% (95%ci 3.5–7.6). GF was determined when ANC had
not reached 0.5  10*9/L by day 21 (primary GF, n 5 21) or
when ANC decreased irreversibly after engraftment (secondary
GF, n 5 4). CI of GF was 2.5%, 6.8% and 23.4% after SCT
from siblings, MUD or alternative donors, respectively (p \
0.001) but was similar following myeloablative or reduced-intensity
conditioning (5.7% and 4.6%, respectively). Pts with a predominant
donor population in chimerism testing were given donor cell boost
with no additional conditioning (n 5 10). Pts with a predominant
host populationwere given autologous back-up cells (n5 8) or a sec-
ond SCT from a different donor (sibling-1, haplo-3, MUD-1) with
nonmyeloablative conditioning. 18 pts survived. 1 week after sec-
ond graft infusion and are evaluable for engraftment. 16 pts en-
grafted within a median of 10 days (range, 5–15). The probability
and pace of engraftment was similar in the different approaches.
11 pts (44%) were able to be discharged home and 14 died; 2 early
after diagnosis ofGFwith no intervention, 5 within one week of sec-
ond graft infusion and prior to engraftment, 2 with no engraftment
and 5 early after engraftment from infection (n5 3), organ failure (n
5 1) and GVHD (n 5 1). With a median follow-up of 19 months
(range, 3–68), 6 are alive and 5 additional pts died (relapse-3,
GVHD-1, infection-1). The projected 2-year survival for all pts
was 23% (95%ci 5–41). Interestingly, 4 pts given autologous cells
had donor cell recovery, 1 had spontaneous autologous reconstitu-
tion within 3 weeks, 2 died within 2months (GVHD-1, infection-1)
with persistent donor cells and 1 remained complete donor until she
relapsed 2 years later. In conclusion, treatment of GF with a chime-
rism directed method can salvage a subset of pts with GF. Reserving
autologous and/or donor backup cells or an alternative donor is ad-
visable in pts at high-risk of GF. The observation of allogeneic re-
covery after autologous boost is intriguing and of unknown
mechanism.260
COMPARISON OF INCIDENCE OF SYSTEMIC VIRAL INFECTION (SVI) AND
INVASIVE FUNGAL INFECTION (IFI) IN CHILDREN RECEIVING BUSUL-
FAN BASED REDUCED INTENSITY ALLOGENEIC STEM CELL TRANS-
PLANT (RIAlloSCT) VS. MYELOABLATIVE AlloSCT (MA-AlloSCT) FOR
MALIGNANT AND NON-MALIGNANT DISEASES
Satwani, P., Freedman, J., Baldinger, L., Guerra, J., van de Ven, C.,
Jin, Z.Z., Garvin, J., George, D., Bradley, M.B., Bhatia, M.,
Schwartz, J., Wolownik, K., Foley, S., Hawks, R., Cairo, M.S. Morgan
Stanley’s Children’s Hospital New York-Presbyterian, Columbia Univer-
sity, New York, NY.
We have previously demonstrated the safety and efficacy of RIAl-
loSCT in pediatric recipients (DelToro/Cairo et al, BMT, 2004;
Bradley/Cairo et al, BMT, 2007). RIAlloSCT in adults is associated
with a significant decrease in early bactermia (Junghanns et al,
BBMT, 2002), but not in incidence of IFI or CMV (Fukuda et al,
Blood 2003; Junghanns et al, Blood 2002). Date is lacking on inci-
dence and timing of SVI and IFI in children undergoing RIAl-
loSCT. We compared the incidence of SVI and IFI in children
receiving busulfan (BU)-based RIAlloSCT (group-A) vs. MA-Al-
loSCT (group-B) for various malignant and non-malignant dis-
eases. Regimens in group-A were BU (6.4–8 mg/kg)/Fludarabine
(FLU) (150–180 mg/m2) 6 ATG (n 5 36) and regimens in
group-B were BU (12.8–16 mg/kg)/FLU (150–180 mg/m2) 6
Alemtuzumab (n 5 17) vs. MA regimen (group-B) consisting of
BU (12.8–16 mg/kg)/Cyclophosphamide (120–200 mg/kg) or Mel-
phalan (135 mg/m2)6 ATG (n5 34). Median age: 7 yrs in group-A
(0.5–21) and 4.5 yrs in group B (0.3–21), respectively. Stem cell
source: UCB (group-A 5 31, group-B 5 20), PBSC (group-A 5
18, group-B5 6), BM (group-A5 4, group-B5 8). Donor source:
HLA-matched sibling (group-A 5 14, group-B 5 8), partially
matched related (group-A 5 3, group-B 5 2), unrelated (group-A
5 37, group-B 5 24). GVHD prophylaxis consisted of tacroli-
mus/MMF for most patients (Osunkwo/Cairo et al, BBMT,
2004). CMV at risk recipients received ganciclovir/foscarnet (Sher-
eck/Cairo et al, PBC, 2006) and most received antifungal prophy-laxis with liposomal amphotericin B until day -100 (Roman/Cairo
et al, PBC, 2007). Median follow-up: 782 days group-A/349 days
group-B. Median time to myeloid engraftment: 19 days group-A
& 20 days group-B. Incidence of aGVHD: 33% group-A/46%
group-B. Incidence of cGVHD: 31% group-A/25% group-B. SVI
were present in 27/53 pts (50%) in group-A and 22/34 pts (64%)
in group-B (p5ns); Table-1. IFI were present in 5/53 pts (9.4%)
in group-A, 5/34 pts (15%) in group-B (p5ns); Table-1. 3 pts
died 1 of RSV pneumonitis in group-A and 1 each of invasive asper-
gillus in group- A and B, respectively. Incidence of mortality sec-
ondary to SVI and IFI was 2/53 pts (3.7%) group-A, 1/34 pts
(2.9%) group-B. The estimated 1 yr OS was 77.7% (CI95: 65.7–
89.4) group-A and 63.8% (CI95: 57.4–80.3, p5ns) group-B. While
the incidence of SVI and IFI was similar in children undergoing RI
vs. MA-AlloSCT, further analysis is required to determine the im-
pact of RI conditioning on timing and mortality of SVI and IFI.
Group-A Group-B
Infection N 5 53 (%) N 5 34 (%)Adenovirus 5 (9.4) 2 (6)
CMV 5 (9.4) 5 (14)
EBV 0 0
RSV 10 (18) 6 (18)
Para-Influenza 4 (8) 5 (14)
Varicella 5 (9.4) 0
HSV 5 (9.4) 2 (6)
Influenza 2 (3.7) 2 (6)
BK-virus 7 (13) 9 (26)
Rota virus 4 (7.5) 2 (6)
Candida spp. 5 (9.4) 1 (3)
Asperigillus 3 (5.6) 0
Other fungii 1 (0.2) 1 (3)
Viral1fungal 14/31 (46)-UCB,
10/15 (62)-MRD, 4/7
(57)-MUD12/20 (60)-UCB,
8/10 (70)-MRD, 4/4
(100)-MUD261
THE PREVALENCE AND DETERMINANTS OF THE USE OF COMPLEMEN-
TARY AND ALTERNATIVE MEDICINE IN HEMATOPOIETIC STEM CELL
TRANSPLANTATION PATIENTS
Aksoy, S., Kocal, N., Akdogan, S., Ozdemir, E. Hacettepe University In-
stitute of Oncology, Ankara, Turkey.
Background: The aim of this study was to explore the use of
complementary and alternative medicine (CAM) in hematopoietic
stem cell transplantation (HSCT) patients.Methods: A descriptive
survey design was developed. Data was collected through a descrip-
tive questionnaire from 85 patients in outpatient HSCT clinic. Pa-
tients who underwent autologous or allogeneic stem cell
transplantation for hematological malignancies and were at least
100 days post-transplantation were included in this study. Results:
Seventy-two (55 male, 17 female) autologous and 13 (9 male, 4 fe-
male) allogeneic HSCT patients were included in the study. The
median age was 46 (range; 19–80) and median period of time
from the HSCT to evaluation was 24 months (range 4–86).
Thirty-six (42.4%) patients declared the use of some form of
CAM.
Median age of CAM using patients was 36 (range; 19–80) while
the others’ was 50 (range; 23–69) (p 5 0.14).
Patients treated with autologous HSCT reported more frequent
use of some form of CAM than the allogeneic ones (45.8% vs.
%23.1%) (p 5 0.10).
Females (66.7% vs. 34.9%) (p 5 0.01) and higher educated pa-
tients (52.9% vs. 26.5%) (p 5 0.013) used CAM more frequently
than the others. Married patients used CAM less frequently than
the others (35.9% vs. 61.9%) (p 5 0.01).
Herbal medicines and remedies were the most commonly used
CAM therapies. Urtica Dioica, Nigella Sativa and grape seed
were themost commonly used ones. The source of CAM-related in-
formation was mainly friends/family and the media. The majority
used CAM to increase the body’s ability to fight cancer or improve
